Cellceutix Corp. (CTIX.OB) “Low Key” About Product Developments
Yesterday we had a discussion with Mr. Leo Ehrlich, Chief Financial Officer of Cellceutix. Mr. Ehrlich is a very low-key gentleman, but inspired us to want to continue research into CTIX. The first item of discussion in our conversation included the fact that a major cancer hospital (no name was mentioned) will be doing the clinical studies on Kevetrin, their flagship product designed to treat cancer cells that do not respond to typical treatments. Cellceutix hopes that the clinical studies will commence in the third or fourth quarter of this year. Which quarter the studies will begin is dependent on…